Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 5/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ADH1B | P00325 | 1/20 | 0.39 |
| ▸ | ADH1C | P00326 | 1/20 | 0.39 |
| ▸ | ADH1A | P07327 | 1/20 | 0.39 |
| ▸ | ADH4 | P08319 | 1/20 | 0.39 |
| ▸ | ADH7 | P40394 | 1/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22649557 | 1.00 | OPRM1 (0.50) | OPRM1FAAHCNR1CNR2SPHK1 | |
| SCHEMBL28813965 | 1.00 | OPRM1 (0.50) | OPRM1FAAHCNR1CNR2SPHK1 | |
| SCHEMBL471924 | 1.00 | OPRM1 (0.50) | OPRM1FAAHCNR1CNR2SPHK1 | |
| SCHEMBL15380779 | 1.00 | OPRM1 (0.50) | OPRM1FAAHCNR1CNR2SPHK1 | |
| SCHEMBL6425397 | 1.00 | OPRM1 (0.50) | OPRM1FAAHCNR1CNR2SPHK1 | |
| SCHEMBL3316528 | 1.00 | OPRM1 (0.50) | OPRM1FAAHCNR1CNR2SPHK1 | |
| SCHEMBL24090459 | 1.00 | OPRM1 (0.50) | OPRM1FAAHCNR1CNR2SPHK1 | |
| SCHEMBL5538153 | 1.00 | OPRM1 (0.50) | OPRM1FAAHCNR1CNR2SPHK1 | |
| SCHEMBL610212 | 0.97 | OPRM1 (0.52) | OPRM1FAAHCNR1CNR2SPHK1 | |
| SCHEMBL18106104 | 0.97 | OPRM1 (0.52) | OPRM1FAAHCNR1CNR2SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109651886-A | A kind of zinc oxide base nano particle ink and its application | TCL集团股份有限公司 | 2019-04-19 | — | — | CN | claimed |
| CN-109651886-A | A kind of zinc oxide base nano particle ink and its application | TCL集团股份有限公司 | 2019-04-19 | — | — | CN | disclosed |
| EP-2132167-B1 | METHOD FOR THE PRODUCTION OF beta-KETONITRILES | BASF SE (DE) | 2013-12-25 | — | — | EP | disclosed |
| US-8501748-B2 | Method for the production of β-ketonitriles | BASF SE (DE) | 2013-08-06 | — | — | US | disclosed |
| US-20130005970-A1 | Method for the production of beta-ketonitriles | BASF SE (DE) | 2013-01-03 | — | — | US | disclosed |
| US-8309751-B2 | Method for the production of β-ketonitriles | BASF SE (DE) | 2012-11-13 | — | — | US | disclosed |
| US-20100105903-A1 | Method for the production of beta-ketonitriles | BASF SE (DE) | 2010-04-29 | — | — | US | disclosed |
| EP-2132167-A1 | METHOD FOR THE PRODUCTION OF -KETONITRILES | BASF SE (DE) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008107397-A1 | METHOD FOR THE PRODUCTION OF β-KETONITRILES | BASF SE (DE) | 2008-09-12 | — | — | WO | disclosed |
| EP-1732533-A1 | THYROID RECEPTOR AGONISTS | KARO BIO AB (SE) | 2006-12-20 | — | — | EP | disclosed |
| US-20040229871-A1 | Phthalimido derivatives and a process for their preparation | CESURA ANDREA (CH) | 2004-11-18 | — | — | US | disclosed |
| WO-2004039762-A1 | PHENETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2004-05-13 | — | — | WO | disclosed |
| US-6660736-B2 | MAO-B inhibitors | HOFFMANN-LA ROCHE INC. | 2003-12-09 | — | — | US | disclosed |
| EP-1200462-A2 | USE OF QUINIC, SHIKIMIC ACIDS AND THEIR DERIVATIVES FOR PREPARING MANNOSE RECEPTOR LIGANDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001009173-A2 | USE OF QUINIC, SHIKIMIC ACIDS AND THEIR DERIVATIVES FOR PREPARING MANNOSE RECEPTOR LIGANDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNR S) (FR) | 2001-02-08 | — | — | WO | disclosed |
| US-5827501-A | INERT TRIARYLMETHYL FREE RADICAL CONTRAST AGENTS FOR ELECTRON SPIN RESONANCE (ESR) ENHANCED MAGNETIC RESONANCE (EMR) IMAGING | NYCOMED IMAGING AS (NO) | 1998-10-27 | — | — | US | disclosed |
| US-5599522-A | CONTRAST ENHANCING AGENTS | NYCOMED IMAGING AS (NO) | 1997-02-04 | — | — | US | disclosed |
| EP-0515458-B1 | TRIARYLMETHYL RADICALS AND THE USE OF INERT CARBON FREE RADICALS IN MRI | NYCOMED INNOVATION AB (SE) | 1995-08-23 | — | — | EP | disclosed |
| EP-0515458-A1 | TRIARYLMETHYL RADICALS AND THE USE OF INERT CARBON FREE RADICALS IN MRI. | HAFSLUND NYCOMED INNOVATION (SE) | 1992-12-02 | — | — | EP | disclosed |
| WO-1991012024-A1 | TRIARYLMETHYL RADICALS AND THE USE OF INERT CARBON FREE RADICALS IN MRI | HAFSLUND NYCOMED INNOVATION AB (SE) | 1991-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005970-A1 | Method for the production of beta-ketonitriles | AKR1C3, AKR1C4, AKR1C1 | OPRM1 3316/4885FAAH 470/4885CNR1 209/4885 |
| US-20040229871-A1 | Phthalimido derivatives and a process for their preparation | MAOB, MAOA, CYP4B1 | OPRM1 281/4885FAAH 947/4885CNR1 1441/4885 |
| US-20100105903-A1 | Method for the production of beta-ketonitriles | AKR1C3, AKR1C4, AKR1C1 | OPRM1 3316/4885FAAH 470/4885CNR1 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.